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S U M M A R Y
Objectives: To determine the prevalence and the sociodemographic characteristics and sexual behavior
risk factors for human papillomavirus (HPV) infection in a hospital-based cohort of women in Saudi
Arabia.
Methods: Cervical specimens and questionnaire data were collected from women attending clinics in
Riyadh, Saudi Arabia. Cervical specimens were examined for abnormal cytology using a standard Pap test
and for the presence of HPV-DNA using PCR and reverse line blot hybridization tests.
Results: Approximately 73% of the 400 women tested were Saudi nationals. Nearly 50% were under
40 years old (range 22–80 years, mean  standard deviation 41.20  10.43 years). Approximately 17% of
the women were HPV-positive. The most commonly detected HPV types were HPV-18 (34%) and HPV-16
(19%), with multiple infections detected in 10% of positive specimens. Multivariate analyses revealed that
smoking and multiple partners were signiﬁcant risk factors for HPV infection (p < 0.01).
Conclusions: Because of societal challenges and an unsubstantiated assumption of low HPV prevalence,
few studies have examined sociodemographic characteristics or sexual behaviors associated with HPV in
Saudi women. However, a high prevalence of HPV infection was found, with smoking and multiple
partners as signiﬁcant risk factors, in this hospital-based cohort of predominantly Saudi women.
 2016 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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The presence of human papillomavirus (HPV) infection, a key
etiological factor in carcinoma of the cervix and other mucosal
epithelia, is associated with approximately 4.8% of all human
cancers,1 posing a signiﬁcant morbidity and mortality risk
worldwide. Papillomaviruses belong to a family of small, non-
enveloped viruses with a double-stranded DNA genome of
approximately 7.9 kb.2 HPV establishes productive infections only
in keratinocytes of the skin or mucous membranes. More than
180 genotypes of HPV have been sequenced, and these are* Corresponding author. Tel.: +966 11 442 7867; fax: +966 11 442 4519.
E-mail address: ahdal@kfshrc.edu.sa (M.N. Al-Ahdal).
http://dx.doi.org/10.1016/j.ijid.2016.04.004
1201-9712/ 2016 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).classiﬁed as either low-risk HPV (LR-HPV) or high-risk HPV (HR-
HPV), depending on their oncological potential for transforming
cells. Benign hyperproliferative lesions or genital warts are caused
by LR-HPVs, while HR-HPVs are strongly associated with
premalignant and malignant cervical lesions that lead to different
types of cancers such as cervical, vulvar, vaginal, penile,
oropharyngeal, and anal cancers.3,4
Cervical cancer is the eighth most frequent cancer among
women in Saudi Arabia aged 15 to 44 years,5 and according to the
World Health Organization, 6.51 million Saudi women 15 years
and older are at risk of developing cervical cancer.6 An estimated
152 Saudi women are diagnosed with cervical cancer and 55 die
from the disease every year. By contrast, the prevalence of HPV in
Saudi Arabia and many developing countries remains unknown or
controversial. However, approximately 2.2% of women living inciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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infection, with approximately 68.5% of invasive cervical cancers in
Asia attributable to HPV-16 or HPV-18.6 In Saudi Arabia, the
prevalence of HPV infection is under debate. Some researchers
have suggested that Saudi Arabia has the lowest HPV infection rate
in the world (e.g., 1.9 cases/100 000 women),7 but others claim a
much higher rate.8–12
Cervical cancer is preventable, and with an early diagnosis, it
may also be curable. Unfortunately, most women in developing
countries, including Saudi Arabia, remain undiagnosed until
advanced stages, which decreases survival rates.13 Therefore, the
present study was conducted to report the prevalence of HPV
infection in a hospital-based cohort of women in Saudi Arabia and
to establish a sociodemographic proﬁle and sexual health behavior
as risk factors for HPV infection.
2. Materials and methods
2.1. Participants, specimens, and data collection
Women who attended the Primary Care Clinic (namely, Family
Medicine) or the Obstetrics and Gynecology Clinic at King Faisal
Specialist Hospital and Research Centre (KFSHRC) in Riyadh, Saudi
Arabia, for routine cervical examinations from November 2013 to
November 2015 were included in this 2-year study. These clinics treat
persons of all socioeconomic classes who are eligible for treatment
in this hospital. The inclusion criteria for participation in the study
were women who were married, divorced, or widowed, and the
exclusion criteria were women who were pregnant or virgin. Given
religious and cultural constraints, Saudi women who have never
married could not be recruited for this study; therefore, all women
who had never married were excluded from the study to avoid bias.
Women who did not ﬁll in the questionnaire in its entirety were also
excluded from the study; thus, all survey questions were answered.
Cervical specimens were collected using a cytobrush. Two
cytobrushes were used to collect the specimens: the ﬁrst was
transferred into a vial containing liquid-based cytology transport
medium (PreservCyt; ThinPrep Pap Test Boxborough, MA, USA) for
use in a routine Papanicolaou (Pap) test; the second cytobrush was
transferred into a vial containing RNAlater stabilizing reagent
(Qiagen, Valencia, CA, USA) for use in molecular detection
experiments. The cervical specimens were examined for normal
or abnormal cytology, and the stages of abnormal cytology were
identiﬁed according to the Bethesda classiﬁcation,14 as follows:
negative for intraepithelial lesion (NIEL), atypical squamous cells
of undetermined signiﬁcance (ASCUS), low-grade squamous
intraepithelial lesion (LGSIL), high-grade squamous intraepithelial
lesion (HGSIL), and cervical carcinoma.
Questionnaires were completed by the enrolled participants
and were collected by a clinical coordinator during the partici-
pants’ clinical visits. Women who agreed to participate in the study
ﬁlled out the questionnaire in its entirety, leaving no question
unanswered.
2.2. Ethics approval
This study was approved by the Ofﬁce of Research Affairs (ORA)
of King Faisal Specialist Hospital and Research Centre (RAC #2130
033), and written informed consent was obtained from each
participant.
2.3. DNA extraction from cervical specimens
Cervical cells were collected using centrifugation, and total
genomic DNA was extracted using a Gentra Puregene Cell Kit
according to the manufacturer’s instructions (Qiagen, Hilden,Germany). The extracted DNA was eluted in 50 ml of RNase/DNase-
free water. The quality and quantity of the extracted DNA were
determined using a NanoDrop spectrophotometer (NanoDrop
Technologies, Wilmington, DE, USA). The quality of DNA extracted
from cervical specimens was determined with b-globin primers.
The ampliﬁed products were visualized using 1% agarose gels
stained with ethidium bromide.
2.4. HPV detection
The MY09/MY11 and GP5+/GP6+ primer sets were used to
target sequences located within the L1 region. The MY09/11
primer set targeted a 450-bp conserved sequence and was used for
the ﬁrst round of PCR. The GP5+/GP6+ primer set targeted a 150-bp
sequence within the 450-bp product and was, therefore, used for
nested PCR. The internal control was the b-globin gene, the
positive controls were HeLa and SiHa cells, and the negative
controls were UltraPure DNase/RNase-free water and HEK293
cells. Positive amplicons were sequenced for conﬁrmation at the
Sequencing Core Facility of KFSHRC using an ABI3730XL sequencer
(Applied Biosystems, Foster City, CA, USA).
2.5. Genotyping by reverse line blot (RLB) hybridization
The oligoprobes (n = 23; C12 Aminolink) were synthesized as
described previously.15 The genotyping protocol followed has been
published previously.16 Brieﬂy, oligoprobes were spotted on a
carboxyl-coated nylon membrane (Biodyne C 0.45 mm; Pall
Corporation, Pensacola, FL, USA). For hybridization, biotinylated
PCR products were added to the membrane. Subsequently, the
membrane was incubated with an anti-ﬂuorescein peroxidase
conjugate. HPV genotypes were detected using an enhanced
chemiluminescence kit.
2.6. Data and statistical analyses
Demographic information and sexual behavior data were
collected using a questionnaire provided to each participant.
Previously published papers were used to identify the risk factor
variables used in the present study.17–20 The demographic
variables included age, religion, marital status, education, nation-
ality, smoking habit, and income. The sexual variables included age
at ﬁrst intercourse, number of sexual partners, number of children,
contraceptive use, and duration and type of contraception used.
All data collected were stored and analyzed using IBM SPSS
Statistics version 22 software (IBM Corp., Armonk, NY, USA).
Univariate and descriptive statistics were used to estimate the
proportions. Signiﬁcant associations between HPV status and study
variables were assessed using a Chi-square test. Logistic regression
modeling was used to determine the adjusted odds ratios and 95%
conﬁdence intervals (95% CI) to estimate the relative odds for
demographic and sexual behavior variables and smoking status.
Variables that were signiﬁcant in univariate analyses and variables
that were considered relevant based on the previous research were
evaluated in a multiple logistic regression model. The ﬁnal model
was created with the inclusion of some risk variables with potential
biological signiﬁcance, which were those that remained statistically
signiﬁcant after adjustment. All p-values reported were two-sided
and were considered to be statistically signiﬁcant at p < 0.05.
3. Results
3.1. HPV prevalence and cytology results
Of the 400 women who were recruited and examined in this
study, approximately 17% (n = 67) tested positive for HPV DNA. The
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and HPV-16 (21%, n = 14), followed by HPV-11 (14%, n = 9), HPV-31
(7.6%, n = 5), HPV-58 (4%, n = 3), HPV-56 (3%, n = 2), and HPV-42
(3%, n = 2). Multiple infections were detected in 10% (n = 7). The
results of the cytology analysis showed that 93% (n = 368) of the
samples were normal (i.e., NIEL), 2% (n = 8) were ASCUS, 3% (n = 12)
were LGSIL, 0.75% (n = 3) were HGSIL, and 0.25% (n = 1) were
cervical cancer. Eleven cervical samples were b-globin-negative
and were excluded from the study. HPV-18 was detected in NIEL,
HGSIL, and cancer samples, HPV-16 was detected in NIEL, ASCUS,
LGSIL, and HGSIL, and HPV-56 was detected in NIEL and ASCUS.
Multiple infections were detected in NIEL, ASCUS, and LGSIL
(Figure 1).
The HPV genotype prevalence stratiﬁed by age revealed a
number of signiﬁcant ﬁndings. First, HPV types varied in women
younger than 40 years old compared with those older than
40 years, and declined signiﬁcantly in women >50 years. HPV-11
infection was most prevalent in the 20–29 years age group, HPV-16
in those aged 40–49 years, and HPV-18 in women aged 50 years.
Multiple infections were most prevalent in women younger than
40 years of age (Figure 2).
3.2. Demographic characteristics
A total of 400 women aged 22–80 years were tested for HPV.
Approximately 50% (n = 195) of the women were under the age of
40 years, with a mean age of 41.20 years (standard deviation (SD)
10.43, 95% CI 40.17–42.22). Most of the women were from Saudi
Arabia (73%, n = 291), followed by the Philippines (7.3%, n = 29) and
Jordan (4.0%, n = 16), with a small percentage (<2%) from Europe,
the Americas, Africa, and South Asia. Nearly 90% (n = 357) of the
women were Muslim, and the remainder were Christians. Most
had a higher level of education (45%, n = 181), with 37% (n = 149)
reporting a secondary school education, 10% (n = 41) an interme-
diate school education, and 7% (n = 28) a primary school education.Figure 1. HPV genotypes and cytology results. The most commonly detected HPV types w
58 (3%), HPV-56 (3%), and HPV-42 (3%). HPV-18 was detected in NIEL, HGSIL, and cancer sa
detected in NIEL and ASCUS samples. Multiple infections were detected in NIEL, ASCUApproximately 40% (n = 158) of these women were in house-
holds with monthly incomes of 5333 USD or more. The monthly
household income was 2666–5333 USD for 40% (n = 161), 1066–
2400 USD for 8% (n = 31), and less than 800 USD for 8.5% (n = 34).
Four percent (n = 16) reported having no income. Most of the
women (87.5%; n = 350) were married, with the remaining either
divorced or widowed. Close to one in three women (30%; n = 119)
reported smoking cigarettes. Table 1 presents these ﬁnding and
shows sociodemographic data according to HPV status.
Bivariate analyses indicated that only smoking was associated
with HPV status. Compared with non-smokers (12.5%), a higher
percentage of smokers (27%) tested positive for HPV (Chi-
square = 12.5, p < 0.0001). The results of a multivariate logistic
regression analysis, after controlling for the confounders of age,
education, and employment, indicated that women who smoked
had approximately 2.5 times higher odds of testing positive for
HPV (Supplementary Material, Table S1).
3.3. Sexual behaviors
The mean age at ﬁrst sexual intercourse was 21.5 years (SD 5.0,
range 11–38 years), with approximately half (51%) having
experienced sexual intercourse by the age of 20 years. Overall,
88% of the women reported having a single sexual partner, and the
remaining women (approximately 12%) reported more than one
sexual partner in their lifetime. Approximately 8% had no children.
Among those who reported having children, the average number of
children was 5.0 (SD 2.5, range 1–15) (Table 2).
HPV positivity was higher in women with three or more lifetime
sexual partners (44%) compared with women who had one partner
(16%). Odds ratios increased with increasing numbers of lifetime
sexual partners (Supplementary Material, Table S1).
Most women (72%, n = 287) reported using some type of
contraception in their lifetime. Among them, the intrauterine
device (IUD) (61%) and birth control pills (37%) were the twoere HPV-18 (34%) and HPV-16 (19%), followed by HPV-11 (13%), HPV-31 (6%), HPV-
mples. HPV-16 was detected in NIEL, ASCUS, LGSIL, and HGSIL samples. HPV-56 was
S, and LGSIL samples.
Figure 2. HPV genotypes and age categories. Multiple infections were highest in the youngest population. HPV-18 was most prevalent among women 50 years old, whereas
HPV-16 was most prevalent among 40–49-year-olds and HPV-11 infection was most prevalent in those aged 20–29 years.
Table 1
Sociodemographic characteristics of the study cohort
HPV-positive 16.8% (n = 67) HPV-negative 83.3% (n = 377) Total % (N = 400) Chi-square (df)
% (n) % (n) % (n)
Age, years 5.8 (4)
20–29 (n = 65) 20.0 (13) 80.0 (52) 16.3 (65)
30–39 (n = 119) 17.0 (20) 83.0 (99) 30.0 (119)
40–49 (n = 123) 17.0 (21) 83.0 (102) 31.0 (123)
50+ (n = 93) 13.0 (13) 86.0 (80) 23.7 (93)
Mean age (SD) 40.3 (10.67) 41.43 (10.38) t-value = 1.002
Religion 2.7 (1)
Christian (n = 43) 25.6 (11) 74.4 (32) 11.0 (43)
Muslim (n = 357) 16.0 (56) 84.0 (301) 89.0 (357)
Nationality 0.28 (1)
Saudi (n = 291) 16.0 (47) 84.0 (244) 73.0 (291)
Non-Saudi (n = 109) 18.0 (20) 82.0 (89) 27.0 (109)
Education 1.6 (3)
Primary (n = 28) 11.0 (3) 89.0 (25) 7.0 (28)
Intermediate (n = 41) 19.5 (8) 80.5 (33) 10.0 (41)
Secondary (n = 149) 19.0 (28) 81.0 (121) 37.0 (149)
Higher (n = 181) 15.5 (28) 84.5 (153) 45.0 (181)
Annual household income (USD) (ref. >5333.40)
<800.01 (n = 34) 20.0 (10) 71.0 (24) 9.0 (34) 4.1 (3)
1066.68–2400.03 (n = 31) 13.0 (4) 87.0 (27) 8.0 (31)
2666.70–5333.40 (n = 161) 16.0 (26) (84.0 (135) 42.0 (161)
>5333.40 (n = 158) 17.0 (27) 83.0 (131) 41.0 (158)
Marital status 0.72 (2)
Married (n = 350) 16.3 (57) 83.7 (293) 87.5 (350)
Divorced (n = 38) 18.4 (7) 81.6 (31) 9.5 (38)
Widowed (n = 12) 25.0 (3) 75.0 (9) 3.0 (12)
Smoking status
Yes (n = 119) 27.0 (32) 73.0 (87) 30.0 (119) 12.5 (1)a
No (n = 281) 12.5 (35) 87.5 (246) 70.0 (281)
HPV, human papillomavirus; SD, standard deviation.
a p < 0.001.
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(1.7%). The average duration of contraception use reported was
4 years (SD 3.2 years), with a maximum use of 25 years
(Table 2).Table 2 presents sexual behavior data according to HPV status.
Bivariate analyses indicated that among sexual behavior variables,
only the number of sexual partners was signiﬁcantly associated
with HPV status (Chi-square = 8.8, p < 0.01).
Table 2
Sexual behavior characteristics of the study cohort
HPV-positive (n = 67) HPV-negative (n = 377) Total % (N = 400) Chi-square (df)
Age at ﬁrst intercourse, mean (SD) 22.0 (4.89) 21.42 (4.97) t-value = 0.74
Lifetime sexual partners 8.8 (2)a
1 (n = 352) 16.0 (56) 84.0 (296) 88.4 (352)
2 (n = 30) 13.3 (4) 86.7 (26) 7.5 (30)
3 (n = 16) 44.0 (7) 56.0 (9) 4.0 (16)
Number of sexual partners, mean (SD) 1.3 (0.76) 1.14 (0.48) t-value = 1.6
Number of children, mean (SD) 5.44 (2.48) 4.79 (2.56) t-value = 1.75
Contraceptive use 0.38 (1)
Yes 16.0 (46) 84.0 (241) 72.0 (287)
No 19.0 (21) 81.0 (92) 28.0 (113)
Contraception type 3.5 (3)
None used 19.0 (21) 81.0 (92) 28.0 (113)
Condom 0.0 (0) 100.0 (5) 1.3 (5)
IUD 14.0 (24) 86.0 (151) 44.0 (175)
Oral pills 21.0 (22) 79.0 (85) 27.0 (107)
Contraception use duration in months, mean (SD) 50.41 (50.22) 47.58 (35.57) t-value = 0.46
HPV, human papillomavirus; SD, standard deviation; IUD, intrauterine device.
a p < 0.01.
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The present study determined the prevalence of genital HPV
genotypes among women in a hospital-based cohort in Saudi
Arabia, as well as the sociodemographic characteristics and sexual
behaviors that may be risk factors for HPV infection, which can lead
to cervical cancer. Approximately 17% of the women tested positive
for HPV, which is in agreement with studies reporting a higher HPV
prevalence in Saudi Arabia, as opposed to those suggesting a very
low prevalence. Among those reports claiming a higher prevalence
of HPV in Saudi Arabia, one recent study screened 519 cervical
specimens using PCR and a reverse line blot hybridization assay and
found that 164 (31.6%) women were positive for HPV.16 The results
of a recent observational cross-sectional study investigating the
prevalence of HPV in women during their routine gynecological
examinations at three hospitals in Saudi Arabia, detected HPV DNA
in 9.8% of the women (n = 417, aged 15 years). The HPV test was
conducted using PCR, and typing was performed using the SPF10
DEIA/LiPA25 system.9 The discrepancy among the reported results
may be attributable to the different detection techniques used in
the studies. It was noticed that most studies reporting high rates of
HPV used ampliﬁcation techniques (e.g., PCR and nested PCR),9–11
whereas many studies reporting a low prevalence used hybridiza-
tion techniques (e.g., in situ hybridization and HC-2).7 Hybridiza-
tion techniques are known to have lower detection limits because
they detect the exact amount of DNA present in the specimen. By
contrast, the ampliﬁcation techniques amplify a minute amount of
DNA to millions of copies for detection. An additional plausible
explanation is that the rate of HPV-positive women may be
expected to be lower in the target group, which was composed of
women attending primary care clinics who had no current
gynecological problems, whereas the rate of HPV-positive women
may be expected to be higher in referral cases or in women
presenting in the clinic with gynecological problems such as
bleeding, pain in the lower belly or pelvis, etc.
The most commonly detected HPV types in the present study
were HPV-18 (34%) and HPV-16 (19%), followed by HPV-11 (13%),
HPV-31 (6%), HPV-58 (4%), HPV-56 (3%), and HPV-42 (3%). These
results are in agreement with those from two recent observational
cross-sectional studies conducted in Saudi Arabia showing that the
most prevalent HPV types included HPV-68/73, HPV-18, HPV-16,
HPV-6, HPV-42, HPV-53, HPV-54, and HPV-45.9,11 Multiple infec-
tions were also detected in the present study in 11% of the HPV-
positive samples and were highest in the youngest age group (20–29
years). A number of studies have associated multiple HPV infections
with a heightened risk for the development or progression of cervicaldysplasia and carcinoma; therefore, follow-up for patients diag-
nosed with multiple infections is essential.21,22
The HPV genotype prevalence stratiﬁed by age indicated that
that types of HPV most prevalent in women younger than 40 years
old differed from those in women aged over 40 years, and that
prevalence declined signiﬁcantly in women aged >50 years. This
ﬁnding is in agreement with a number of previous reports and is
thought to be correlated with several factors, including a reduced
number of sexual partners in older women, as well as slowly
developing host immunity and viral clearance.23,24 A worldwide
meta-analysis of age-speciﬁc HPV prevalence revealed that women
younger than 34 years have a higher rate of HPV infection than
those aged 35 years and older. Furthermore, the HPV prevalence
below age 25 or 35 years is higher in less developed than in more
developed countries. But overall, there is a trend of continuous
decline with increasing age.25,26
The results of this study also revealed that smoking is a very
strong predictor of HPV infection (p < 0.001). Although it has been
reported extensively that smoking is associated with cervical cancer,
further studies are required to evaluate smoking as a risk factor for
HPV infection.27,28 This ﬁnding underscores the need to increase
awareness of the adverse consequences of smoking among women.
Unfortunately, smoking status (yes/no) was tested, but not smoking
duration, frequency, or type or number of cigarettes consumed.
Therefore, a larger-scale follow-up study will be conducted to
investigate smoking status as a predicative factor for HPV infection.
The relationship between sexual behavior and the prevalence of
HPV infection was evaluated in women attending KFSHRC clinics.
Compared with women who had one partner (16%), HPV positivity
was higher in women with three or more lifetime sexual partners
(44%). The odds ratio increased with an increasing number of
lifetime sexual partners. It is well known that having multiple
sexual partners is a risk factor for HPV infection.29,30
The association of contraceptive use and HPV infection varied
slightly among the methods employed. For example, 21% of the
participants using oral contraceptive pills tested positive for HPV
and 14% of IUD users tested positive. However, 19% of the women
using no contraception also tested positive for HPV. It was
previously suggested that the use of oral contraceptive pills may be
a risk factor for cervical intraepithelial neoplasia because oral
contraceptives may lead to DNA damage or alter the susceptibility
of cells to oncogenic viruses or chemical carcinogens.31,32
Interestingly, in the present study, 100% of the few women who
used condoms were protected against HPV infection. Unlike
Western societies, condom use is low in the Saudi population. The
results of this study indicate that condom use in Saudi Arabia
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sexually transmitted infections.
The small sample size of positive HPV cases (n = 67) presented a
limitation to the analyses of the data collected, restricting the
available analytical approaches and occasionally resulting in wide
95% CI ranges and less precision. Additionally, all women who
agreed to participate in this study completed the entire survey. The
exclusion of partially completed surveys might have introduced a
selection bias. Another limitation is that the women receiving care
at KFSHRC usually have higher incomes and higher education
levels than the population in general. Nevertheless, this study is
one of the ﬁrst to address HPV infection among women in a
conservative society in which merely collecting sexual behavior
information and cervical specimens remains challenging. Thus, the
present ﬁndings on HPV prevalence and sociodemographic and
sexual behavior risk factors are valuable.
In conclusion, there is a dearth of studies examining HPV
prevalence and sociodemographic characteristics in Saudi Arabia.
This report is among the few providing sociodemographic and
sexual behavior data from Saudi Arabia. Such valuable information
may pave the way for understanding HPV infection in a
conservative society, which will lead to a better understanding
of the infection in general and, therefore, to its prevention. Future
research from this group will include a national study with
extensive sociodemographic and sexual behavior data covering all
13 provinces of Saudi Arabia. This is to establish a strong database
that can be used to measure the HPV prevalence and the need for
awareness and vaccination programs.33
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